Does pro-inflammatory cytokine signaling reduce circulating iron despite adequate iron stores?

The regulation of iron homeostasis is significantly altered during inflammatory states, a process primarily mediated by pro-inflammatory cytokines such as Interleukin-6 (IL-6), Tumor Necrosis Factor-alpha (TNF-alpha), and Interleukin-1 (IL-1). This signaling leads to a "functional iron deficiency," where systemic iron levels are low despite adequate or even elevated total body iron stores.

Mechanistic pathways of iron sequestration

The reduction in circulating iron is driven by a precise molecular cascade initiated by cytokine signaling:

• Hepcidin Induction via IL-6/STAT3: IL-6 is the primary driver of hepcidin (HAMP) transcription. Upon binding to its receptor, IL-6 activates the JAK/STAT3 pathway, causing STAT3 to phosphorylate and translocate to the nucleus, where it binds directly to the hepcidin promoter. This mechanism is both necessary and sufficient for inflammation-induced hepcidin elevation.
• Ferroportin Degradation: Hepcidin acts as the master regulator of iron efflux. High circulating hepcidin binds to ferroportin—the only known cellular iron exporter—on the surfaces of macrophages, hepatocytes, and enterocytes. This binding triggers the internalization and lysosomal degradation of ferroportin, effectively "locking" iron inside these cells.
• Ferritin Upregulation: Ferritin, the primary iron-storage protein, acts as an acute-phase reactant. Cytokines like IL-6 and TNF-alpha increase ferritin levels through two pathways: stimulating the transcription of the ferritin heavy chain (FTH) via NF-kB and STAT3, and overriding the standard iron-dependent translational repression (the IRE/RP system). This allows for increased ferritin production even when iron availability is theoretically low.

Clinical and physiological evidence

• Nutritional Immunity: This sequestration is an evolutionarily conserved defense mechanism known as "nutritional immunity," designed to withhold iron from circulating pathogens that require it for replication.
• Biomarker Profiles: In patients with chronic inflammation or sepsis, clinical markers typically show high serum ferritin (>100–200 ng/mL) alongside low serum iron and low transferrin saturation (TSAT <20%). Studies in pediatric sepsis have shown strong correlations between IL-6 levels and ferritin (r = 0.54 to 0.702), reflecting the intensity of this inflammatory response.
• Functional Iron Deficiency: Bone marrow biopsies in inflammatory states often reveal abundant iron stores within macrophages, yet erythroid precursors remain iron-deficient because the hepcidin-ferroportin blockade prevents the mobilization of those stores for red blood cell production.

Bottom line

Pro-inflammatory cytokine signaling, specifically through the IL-6/STAT3 axis, directly increases hepcidin and ferritin levels. This results in the degradation of ferroportin and the sequestration of iron within cellular stores, significantly reducing circulating iron availability even when total body iron is sufficient. This process is the fundamental cause of anemia of inflammation.